论文部分内容阅读
目的:进一步探讨前列腺素El(PGEl)对病毒性肝炎的疗效.方法:对95例慢性乙型肝炎、肝炎肝硬化及重症肝炎在综合护肝治疗的基础上加用PGEl治疗,疗程14～21d,另设对照组90例.结果:PGEl治疗组中血清总胆红素(SB)的降低明显优于对照组(P<0.05),在慢性肝炎病例组中,治疗组中ALT的下降显著低于对照组(P<0.05);而在重症肝炎组中.虽然两组的病死率无显著性差异.但治疗组中[凝血]因子Ⅱ活动度(PTA)及病情好转率均明显优于对照组(P<0.05).结论:PGEl对慢性肝炎、肝硬化及重症肝炎有一定疗效.
Objective: To further explore the efficacy of prostaglandin E1 (PGE1) on viral hepatitis.Methods: 95 cases of chronic hepatitis B, cirrhosis of liver and severe hepatitis were treated with PGEl on the basis of comprehensive hepatoprotective therapy, the course of treatment was 14-21 days , And another 90 patients in the control group.Results: The decrease of serum total bilirubin (SB) in the PGEl group was significantly better than that in the control group (P <0.05). In the chronic hepatitis group, the reduction of ALT in the treatment group was significantly lower (P <0.05), while in the severe hepatitis group, although there was no significant difference in mortality between the two groups, the activity of coagulation factor Ⅱ (PTA) and the rate of improvement in the treatment group were significantly better than those in the control group Group (P <0.05) .Conclusion: PGEl has a certain curative effect on chronic hepatitis, cirrhosis and severe hepatitis.